Can a cancer drug tame a dangerous immune storm?
NCT ID NCT07424222
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests the drug ruxolitinib for a rare but serious condition called IEC-HS, which can happen after CAR-T therapy for cancer. The condition causes a dangerous overreaction of the immune system. The trial will include 16 adults and aims to see if the drug is safe and can control the overreaction.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ruxolitinib (brand name Jakafi), a drug taken orally to calm an overactive immune response.
What this could lead to
If it works, this could point toward a treatment for a rare but serious immune complication after CAR-T therapy.
What could go wrong
This is a very early, small pilot study with only 16 people. It may not show clear benefit, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE EFFECTOR ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS-LIKE SYNDROME (IEC-HS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••